Literature DB >> 17507295

Methylation damage response in hematopoietic progenitor cells.

Ida Casorelli1, Elvira Pelosi, Mauro Biffoni, Anna Maria Cerio, Cesare Peschle, Ugo Testa, Margherita Bignami.   

Abstract

The cellular response to methylation DNA damage was compared in multipotent CD34(+) hematopoietic stem cells and mature CD34(-) cells isolated from cord blood of the same donor. Cytofluorimetric analysis of freshly isolated cord blood cells indicated that both cell types were in the G0/G1 phase of the cell cycle. Quantitative RT-PCR identified a general trend towards high expression of several DNA repair genes in CD34(+) cells compared to their terminally differentiated CD34(-) counterparts. The overexpressed genes included members of the mismatch repair (MMR) (MSH2, MSH6, MLH1, PMS2), base excision repair (AAG, APEX), DNA damage reversal (O(6)-methylguanine DNA methyltransferase) (MGMT), and DNA double strand breaks repair pathways. These differences in gene expression were not apparent in CD34(+) and CD34(-) cells obtained following expansion of CD34(+) cells in a medium containing early acting cytokines. Early progenitor CD34(+) and early precursor CD34(-) cells form the two populations isolated under these experimental conditions, and both contain a significant proportion of cycling cells. The methylating agent N-methyl-N-nitrosourea (MNU) induced similar levels of apoptosis in these cycling CD34(+) and CD34(-) cells. Cytotoxicity required the presence of the MGMT inhibitor O(6)-benzylguanine and the timing of MNU cell death (48 and 72h) was similar in CD34(+) and CD34(-) cells. These data indicate that cycling CD34(+) and CD34(-) cells are equally sensitive to methylation damage. MGMT provides significant protection against MNU toxicity and MGMT and MMR play the expected roles in the MNU sensitivity of these cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507295     DOI: 10.1016/j.dnarep.2007.03.024

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  7 in total

Review 1.  DNA repair fidelity in stem cell maintenance, health, and disease.

Authors:  Chinnadurai Mani; P Hemachandra Reddy; Komaraiah Palle
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-04-04       Impact factor: 5.187

2.  Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.

Authors:  Haiyan Wang; Shanbao Cai; Aaron Ernstberger; Barbara J Bailey; Michael Z Wang; Wenjing Cai; W Scott Goebel; Magdalena B Czader; Colin Crean; Attaya Suvannasankha; Inna Shokolenkoc; Glenn L Wilson; Arthur R Baluyut; Lindsey D Mayo; Karen E Pollok
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

Review 3.  The bright and the dark sides of DNA repair in stem cells.

Authors:  Guido Frosina
Journal:  J Biomed Biotechnol       Date:  2010-04-08

4.  Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage.

Authors:  Elena Jelezcova; Ram N Trivedi; Xiao-Hong Wang; Jiang-Bo Tang; Ashley R Brown; Eva M Goellner; Sandy Schamus; Jamie L Fornsaglio; Robert W Sobol
Journal:  Mutat Res       Date:  2010-01-22       Impact factor: 2.433

5.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

Authors:  Anne-Marie Bleau; Dolores Hambardzumyan; Tatsuya Ozawa; Elena I Fomchenko; Jason T Huse; Cameron W Brennan; Eric C Holland
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

Review 6.  Balancing self-renewal against genome preservation in stem cells: How do they manage to have the cake and eat it too?

Authors:  Robert Y L Tsai
Journal:  Cell Mol Life Sci       Date:  2016-02-17       Impact factor: 9.261

7.  Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care.

Authors:  Shi-Ming Tu; Charles C Guo; Diana S-L Chow; Niki M Zacharias
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.